Amaç: Vitamin D eksikliği, solunum fonksiyonlarında bozulma ile ilişkili olabilir. Çalışmamızda Kronik Obstruktif Akciğer Hastalığı (KOAH) hastalarında solunum fonksiyonları, hastalığın şiddeti ve alevlenme sıklığı ile serum Vitamin D düzeyi arasındaki ilişkiyi belirlemeyi amaçladık.
Methods: Seventy consecutive patients with COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II-IV) who presented to our outpatient clinic and thirdty controls entered to the study. Diagnosis of COPD was confirmed according to clinical findings and pulmonary function test. Serum 25-hydroxyvitamin D (25(OH)D levels were measured by immunofluorescence method. Levels <20 ng/ mL defined deficiency. Associations between Vitamin D levels and sex, age, body mass index (BMI), smoking habit, comorbidities, exacerbation frequency were examined.
Results:
The mean age of patients was 60.7 years. The proportion of patients in stages 2 of GOLD was 40 %, in stages 3 was 30 % and stages 4was 30 %. There was no significant difference in serum levels of 25(OH)D between COPD patients and controls. Vitamin D level was 9.3 ±6.0 ng/mL in control group and 9.7± 8.5 ng/mL in GOLD stage 2, 9.6 ± 6.2 ng/mL in stage 3 and 5.1 ±2.4 ng/mL in stage 4. In stage 4, vitamin D levels was significantly lower statistically (p=0.03). Among the COPD patients, lower FEV1 was associated with lower levels of 25(OH)D (p= 0.03). The most frequent comorbidities were hypertension (61.4%) and heart failure (27.1%). Among the COPD patients smoking associated with significantly lower levels of serum 25(OH) D (p=0.04). We find an association with exacerbation frequency in the previous 12 months and levels of 25(OH) D (p=0.02).
INTRODUCTION
Several extra-renal sites, including cells of the adaptive immune system, express the vitamin D receptor and the enzyme, 1-hydroxylase, which converts circulating 25(OH)D into the biologically active form 1,25(OH)2D [1] . Both the innate and adaptive immune systems have been implicated as important elements in the pathogenesis of COPD [2] .
Vitamin D has been shown to affect dendritic cell maturation [3] , T-cell activation and proliferation [4] , Th1 T-cell development [5] and to decrease the expression of pro-inflammatory cytokines and chemokines by e. g. airway epithelial cells [6] . Thus, low local 1,25(OH) 2D levels could potentially contribute to inflammation and susceptibility to infections, [7] . Vitamin D has been shown to be an important regulator of both elements of the immune system [8] . Vitamin D also has been shown to directly affect processes involved in tissue remodelling such as fibroblast proliferation and collagen synthesis [9] , and modulation of matrix metalloproteinase (MMP) levels [10] . All these data show vitamin D has an important role that may be associated with many diseases and functions in other tissues outside the bone metabolism [11] .
Vitamin D deficiency is associated with increased risk of chronic diseases like cancer, autoimmune diseases, diabetes, infectious diseases, cardiovascular diseases and also pulmonary diseases [1] . Vitamin D has been shown to prevent airway inflammation and the development of experimental allergic asthma in mice [12] . It also helps the remodeling of airways and reverses steroid resistance which is important characteristics of COPD [13] .
Low prenatal vitamin D levels may be risk factors for asthma prevalence and it is suggested that vitamin D deficiency could be associated with the severity of asthma [14] . Recent studies show that a substantial proportion of patients with chronic obstructive pulmonary disease have deficient vitamin D levels (<20 ng/mL) [15] . In COPD, the risk of vitamin D deficiency is higher than expected and is linked with disease severity [16] . In a study reported that vitamin D deficiency occurs in over 60% of patients with severe COPD, and is quantitatively related to disease severity [15] . Another has could demonstrated that patients with vitamin D levels below 10 ng/ml had the shortest time to first exacerbation and experienced the highest number of acute exacerbation of COPD [17] . These results suggest that Vitamin D deficiency could be associated with development, progression and exacerbation of COPD.
COPD patients may be considered as having high risk for vitamin D deficiency, because of malnutrition, reduction depends on the time they spent in sunlight at the outside, glucocorticoid-induced catabolic growth and renal dysfunction [18] .
According to World Health Organization data, COPD was the fourth most common cause of death in 2000 and is expected to be the third leading cause of death in 2020 [19] . The prevalence of COPD is increasing and acute exacerbations of COPD and hospital admissions are common and strongly influence disease severity and relative healthcare costs [20] . Therefore, it is important to be able to determine the causes of increasing development of COPD, severity and exacerbations.
The present study was designed to investigate the relationship between serum vitamin D and COPD disease severity and exacerbation frequency in patients with chronic obstructive pulmonary disease (COPD).
METHODS
Written information was provided and written consent was obtained prior to inclusion. The regional ethical committee approved the study. All subjects were recruited from the same geographical area.
The study population was derived among the COPD patients presented to outpatient pulmonary clinic during the period, March 2015. They were selected among 70 consecutive COPD patients determined according to the GOLD classification [21] . Post-bronchodilator ratio of forced expiratory volume in 1 second (FEV1) to vital capacity (VC) <0.70 and FEV1 >80 % (predicted) characterized GOLD 1, 50% ≤ FEV1 <80% GOLD 2, 30% ≤ FEV1 <50 GOLD 3, 30% < FEV1, GOLD4 respectively. The patients, age over 40 years and at least one year follow-up in our clinic.
Exclusion criteria were acute exacerbation in the last month and lack of availability for data on lung function/ exacerbations/ hospitalization the year previous to the inclusion in the study, presence of pulmonary infection, tuberculosis, pleural effusion, congestive heart failure, primary pulmonary hypertension, pulmonary emboli, restrictive airway disease, known autoimmune diseases or any active cancer in the last 5 years and conditions associated with vitamin D metabolism, absorption or taking vitamin D containing medications.
At the enrolment visit, patients underwent clinical examination recording of symptoms, smoking habits, comorbidities, medication use and exacerbations was obtained. Subjects were classified as current, former and never smoking, according to selfreported smoking history. Frequent exacerbations were defined as having ≥2 exacerbations treated with antibiotics and/or oral steroids and/or hospitalization in the last 12 months.
Body mass index (BMI) was calculated as the weight (kg) divided by the square of height (m2), and was categorized as underweight (BMI <18. Descriptive statistics for the continuous variables were presented as Mean, Standard deviation, minimum and maximum values while count and percentages for categorical variables. One way ANOVA was used to compare group means. Duncan multiple comparison test was also used to identify different group means fallow ANOVA. For determination linear relationship among variables, Pearson correlation analysis was carried out. In addition, chi-square test was performed to determine the relationship between categorical variables. Statistical significance level was considered as 5 % and SPSS (ver:13) statistical program was used for all statistical computations.
RESULTS
The characteristics of study population are presented in Table 1 Seventy patients with mean age of 60.7 years and thirty controls with mean age of 57.5 years were studied. No interaction between vitamin D deficiency and gender was found in COPD patients and in controls (p=0.74 p= 0.86).
The proportion of patients in stages 2 of GOLD was 40%, in stages 3 was 30% and stages 4was 30 %. 40% of patients were current, 21.4% former and 38.6% never-smokers. Among COPD patients overall mean FEV1 in percent predicted was 45.4.
Concentrations of 25(OH) D among COPD patients and controls for different explanatory variables are shown in Table 2 . Unadjusted, there was no significant difference in serum levels of 25(OH) D between COPD patients and controls. Vitamin D deficiency (<20 ng/ ml) was 91.4% in COPD patients and 90% in controls. In GOLD stage group II 89.3% -group III 85.7% -group IV 100% respectively. Vitamin D level was 9.3 ±6.0 ng/mL in control group and 9.7± 8.5 ng/mL in GOLD stage 2, 9.6 ± 6.2 ng/mL in stage 3 and 5.1 ±2.4 ng/mL in stage 4. In stage 4 vitamin D levels was significantly lower statistically (p=0,03).
Among the COPD patients, lower FEV1 was associated with lower levels of 25(OH) D (p=0.03) (Figure 1) . Among the COPD patients smoking associated with significantly lower levels of serum 25(OH)D (p= 0.04) (Figure 2 ). The most frequent comorbidities were hypertension (61.4%) and heart failure (27.1%).Vitamin D deficiency (<20 ng/mL) was found in all comorbidities. No interaction between vitamin D deficiency and obesity was found in COPD patients (p= 0.31). In stage 4 COPD, the lower vitamin D level was statistically significant with the underweight group (p=0.035).
The patients 48.6 % were frequent exacerbators (≥2) in the previous year. We find an association with exacerbation frequency in the previous 12 months and levels of 25(OH) D (p=0.02) (Figure 3 ).
Figure3
. Levels of vitamin D in COPD subjects divided according to being hospitalized the previous year (p=0.007).
DISCUSSION
Considering the general population, approximately one billion people worldwide are estimated to be sufficient vitamin D levels [22] . In studies conducted in Europe and the US in the elderly, ranging from 40% to 100% of vitamin D deficiency have been identified [22, 23] . There is not enough data in Turkey although few studies conducted on women were identified ranging from 45-75% for vitamin D deficiency [24, 25] .
Many studies have been conducted to determine the normal range of 25 (OH) D for identifying the Vitamin D deficiency [26] . As a result, it was defined as 'deficient' if the 25 (OH) D level is less than 20 ng/ml, 'insufficient' if it is between 21 and 29 ng/ ml and 'normal' if it is higher than 30 ng/ml [27] .
The relationship between serum vitamin D and pulmonary function has been investigated in many previous studies [28, 29] . Ringbaek et al. reported that 61 patient had Vitamin D deficiency (19.6%), 82 patient had vit D insufficiency (26.4%) in 311 COPD patients. In this study, 25 (OH) D levels were positively correlated with FEV1 in COPD patients [30] .
In a cross-sectional study 49 patients with mild and moderate COPD was determined, only 3 (6%) patients had sufficient vitamin D level (> 30 ng / ml), whereas 29 (59%) patients had vitamin D insufficiency (21-29 ng / ml), 17 (35%) patients had deficiency (<20 ng / ml) [31] . In a study conducted in Norway Vitamin D deficiency was found 34% of controls, 20% of with Stage 2.43% of stage 3 and 55 % of stage 4 patients [32] .
In our study, Vitamin D deficiency (<20 ng/ ml) was 91.4% in COPD patients and 90% in controls. In the patients with GOLD stage II 89.3% -III 85.7% -IV 100% respectively. Compared with other studies, vitamin D levels were much lower in our study.
There are several potential explanations for the increased risk for vitamin D deficiency in COPD patients. The patients with COPD are liable to vitamin D deficiency due to lower duration of outdoor activities and inadequate sunlight exposure. COPD patients may have accelerated skin ageing due to smoking, renal dysfunction, reducing the consumption of milk and milk products, less fat tissue due to wasting and treatment with glucocorticoids, all factors that can affect vitamin D synthesis, storage or catabolism [1] . Long-term oxygen therapy is a predisposition factor of vitamin D deficiency [33] .
In the elderly and healthy subjects, there was a relationship between serum 25-OHD levels and FEV1 value [34, 35] . Among COPD patients overall mean FEV1 in percent predicted was 45.4 and lower FEV1 was associated with lower levels of 25(OH) D.
In patients with more severe COPD, vitamin D deficiency is more prevalent and serum 25 min D levels have also been significantly decreased [15] .
Low levels of serum vitamin D may lead to pulmonary function test deterioration and peak exacerbation of COPD, winter and early autumn have been attributed to low concentration of serum 25(OH)D. Vitamin D was deliberately assessed in the winter season, when levels are supposed to be lowest [36] . The lowest winter vitamin D values may contribute to the marked impact of winter season on both frequency and outcomes of COPD exacerbations [37] . Performed on 198 patients with COPD in the Lung Health Study III study, seasonal changes were determined as mean 13.4 ng / ml [28] .
It is important measuring vitamin D levels in patients and control groups to eliminate seasonal effects at the same time. We looked at vitamin D levels in the same month in patients and the control group. The lower values in patient and control groups may be explained the assessment in March after winter.
Lange et al reported that, the vitamin D level was lower in smokers with COPD patients and has been observed annually over the loss of FEV1 [38] . In our study, among the COPD patients, smoking associated with significantly lower levels of serum 25(OH) D (p= 0.04).
Today, except for smoking cessation therapy, there is a need for new treatment strategies in effective protecting lung function. In several studies, it has been found that vitamin D to have anti-inflammatory effects and to be regulated by enzymes such as matrix metalloproteinases associated with smoking. Vitamin D is also serving as both anti-oxidant and increasing the production of anti-oxidants. Also vitamin D could be effective on oxidative stress caused by smoking [38, 39] .
Vitamin D deficiency has been associated with insulin resistance, hypertension, vascular calcification and left ventricular hypertrophy [40, 41] . In our study, COPD patients with Vitamin D deficiency had HT, heart failure, diabetes, osteoporosis, OSAS and anxiety.
Obesity has in previous studies been a significant predictor of low levels of vitamin D in both COPD patients and subjects without COPD [15, 42] . Vitamin D deficiency has been shown to impair insulin synthesis and secretion in human and animal models of diabetes, suggesting a role in the development of type 2 diabetes, which is one of the common causes of obesity and abdominal obesity [43, 44] . But in our study, no interaction between vitamin D deficiency and obesity was found in COPD patients (p=0.31). In stage 4 COPD, the lower vitamin D level was statistically significant with the underweight group (p= 0.035).
Skeletal muscle weakness is one of the most fundamental systemic effects of COPD and an important determinant of exercise capacity [45] . In severe COPD groups after dissolution in muscle have increased risk of hospital readmission, exacerbations and mechanical ventilation. Also Vitamin D deficiency is an independent risk for mortality of COPD [46] .
Severe deficiency was associated with frequent exacerbations and hospitalization. The lowest winter vitamin D values may contribute to the marked impact of winter season on both frequency and outcomes of COPD exacerbations [36, 37] . Several studies demonstrate that vitamin D plays a role in susceptibility to airway infections [47] .One explanation for this is the already mentioned role of vitamin D in the innate immune response, including its ability to induce the production of antimicrobial peptides [48] . In the current study, we find an association with exacerbation frequency in the previous 12 months and levels of 25(OH) D.
In a study conducted in Belgium, there is evidence that vitamin D supplementation could reduce moderate and severe exacerbations in patients with COPD. High dose vitamin D supplementation has been found to decrease acute exacerbations, but only in patients with severe deficiency [49] . The effect of vitamin D supplementation in COPD is still debated.
In conclusion, the results of this study indicate a relationship between serum 25(OH) D levels and COPD. COPD patients had an increased risk for having vitamin D deficiency. 25(OH) D concentration is statistically significantly lower in COPD patients who are current smokers and who are stage 4 according to GOLD. Severe deficiency is associated with higher probability having frequent exacerbations and hospitalization. The prevention of exacer-
